title: Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.
abstract: This study reviewed the lipid profile of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients in relation to use of antiretroviral therapy (ART), and its different classes of drugs. A total of 190 articles published in peer-reviewed journals were retrieved from PubMed and LILACS databases; 88 of them met the selection criteria and were included in the review. Patients with HIV/AIDS without ART presented an increase of triglycerides and decreases of total cholesterol, low density lipoprotein (LDL-c), and high density lipoprotein (HDL-c) levels. Distinct ART regimens appear to promote different alterations in lipid metabolism. Protease inhibitors, particularly indinavir and lopinavir, were commonly associated with hypercholesterolemia, high LDL-c, low HDL-c, and hypertriglyceridemia. The protease inhibitor atazanavir is apparently associated with a more advantageous lipid profile. Some nucleoside reverse-transcriptase inhibitors (didanosine, stavudine, and zidovudine) induced lipoatrophy and hypertriglyceridemia, whereas abacavir increased the risk of cardiovascular diseases even in the absence of apparent lipid disorders, and tenofovir resulted in lower levels of cholesterol and triglycerides. Although non-nucleoside reverse-transcriptase inhibitors predisposed to hypertriglyceridemia and hypercholesterolemia, nevirapine was particularly associated with high HDL-c levels, a protective factor against cardiovascular diseases. Therefore, the infection itself, different classes of drugs, and some drugs from the same class of ART appear to exert distinct alterations in lipid metabolism.
authors.affiliation: Nutrition Department, School of Public Health, Universidade de São Paulo USP, Sao Paulo, SP, Brazil.
authors.forename: Suelen Jorge
authors.initials: SJ
authors.lastname: Souza
authors.forename: Liania Alves
authors.initials: LA
authors.lastname: Luzia
authors.forename: Sigrid Sousa
authors.initials: SS
authors.lastname: Santos
authors.forename: Patrícia Helen Carvalho
authors.initials: PH
authors.lastname: Rondó
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000097:blood / Q000150:complications; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000150:complications; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D044966:Anti-Retroviral Agents; D008055:Lipids; D018894:Reverse Transcriptase Inhibitors